- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ankylosing spondylitis; Psoriatic arthritis; Chronic plaque psoriasis; Refractory fistulising Crohn Disease.
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 492KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 88KB)
Infliximab – March 2022
Infliximab: Solution for injection 120 mg in 1 mL pre-filled pen, Solution for injection 120 mg in 1 mL pre-filled syringe; Remsima® SC
Last updated
1 July 2022